Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating The Efficacy and Safety of MET097, a Fully-Biased, Ultra Long-Acting GLP-1RA, In People With Overweight or Obesity: A Phase 3, Multi-Center Randomized, Controlled Trial (VESPER-4)

NCT07311850 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07311850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07311850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating The Efficacy and Safety of MET097, a Fully-Biased, Ultra Long-Acting GLP-1RA, In People With Overweight or Obesity: A Phase 3, Multi-Center Randomized, Controlled Trial (VESPER-4)
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 19, 2025
Completion date
April 25, 2028
Enrollment
3,578 (actual)
Sites
161

Conditions

As the registry lists them; a condition with its own page is linked.

obesity and overweight